60 results about "Pentoxifylline" patented technology

The present invention provides a topical composition comprising about 6% to about 15% nifedipine and about 6% to about 15% pentoxifylline for treating severe vascular occlusive wounds. The present invention also provides a method and a kit for treating the vascular occlusive wound by applying the composition to the open wound, and cleaning and dressing the wound at least once daily.

This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

An improved method of treating male erectile dysfunction by enteral administration of a combination of sildenafil citrate and papavarine hydrochloride. An alternate mode of treatment indicated for individuals with known vascular disease includes the contemporaneous administration of pentoxifylline. Further embodiments include administration of zinc monomethionine aspartate.

Methods and compositions are provided for treating vascular depression. The methods involve administering to a subject in need thereof a xanthine derivative in a therapeutically effective amount to treat vascular depression, particularly the xanthine derivatives pentoxifylline or propentofylline. The methods may further include administration of an additional therapeutic agent in combination with the xanthine derivative selected from the group consisting of a selective serotonin reuptake inhibitor (SSRI), a serotonin-norepinephrine reuptake inhibitor (SNRI), and a drug used in the treatment of cerebrovascular disease. Compositions of the invention include pharmaceutical compositions and kits for treating vascular depression in a subject in need thereof that include therapeutically effective amounts of a xanthine derivative and an additional therapeutic agent selected from the group consisting of an SSRI, an SNRI, and a drug used in the treatment of cerebrovascular disease.

This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. The compound of the invention are represented by one of the following structural formulas:The variables for these structural formulas are described herein. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

The invention discloses a refining method for pentoxifylline recycling products. The content of impurities in the pentoxifylline recycling products can be reduced, after the recycling products are refined, the maximum single impurities are reduced to be 0.1% or below, the total impurities are 0.5% or below, the standard of finished pentoxifylline is met, the integral yield is improved, and the reaction cost is reduced. The refining method comprises the following steps: (1) adding water in the pentoxifylline recycling products under the condition of heating, dissolving, adding alkaline liquid to regulate a pH value to be 10-14, adding a reducing agent, insulating, and then cooling and filtering to obtain an alkaline solution, wherein the single impurities in the pentoxifylline recycling products are less than 5%, and the total impurities in the pentoxifylline recycling products are less than 10%; (2) fully mixing the alkaline solution obtained in step (1) with an organic solvent A, thenstanding for layering, and removing an organic phase by evaporation to obtain viscous liquid; and (3) adding an organic solvent B to dissolve the viscous liquid, adding activated carbon, after insulating, filtering the activated carbon, cooling filtrate to the temperature of 20 DEG C or below, and filtering and drying to obtain pentoxifylline.

This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

The invention belongs to the field of medicine, and relates to a pharmaceutical composition containing pentoxifylline and carbazochrome sodium sulfonate and application thereof. The pharmaceutical composition contains the active components pentoxifylline and carbazochrome sodium sulfonate, has the efficacies of diminishing inflammation, arresting bleeding, improving the vascular permeability and the like in treating hemorrhagic hemorrhoids, is obviously superior to the single drugs of pentoxifylline and carbazochrome sodium sulfonate in therapeutic action, and has a synergistic action.

A slow-releasing torental table for treating peripheral obliteration vasculitis, sequelae of arteriosclerosis, and local ischemia is prepared from torental (20-70 wt.%), slow releasing agent (cellulose acetate and / or ethyl cellulose) (30-80 wt.%), and other assistants. Its advantages are high curative effect, durable action and low by-effect.

The invention discloses a nutritional solution formula of aeroponic-cultured lettuces and a preparation method thereof. The nutritional solution formula is prepared from the following raw materials inparts by weight: 0.36-0.88 part of magnesium sulfate, 0.25-0.46 part of soy peptone, 1.8-3.3 parts of fructooligosaccharide, 0.1-0.27 part of pentoxifylline, 0.06-0.15 part of monopotassium phosphate, 0.05-0.12 part of urea, 3.6-5.5 parts of carrot, 2.4-4.2 parts of fish bone meal, 5-8 parts of rhizoma acori graminei, 960-1050 parts of deionized water and 13-19.4 parts of mushroom leftover. The nutritional solution formula and the preparation method disclosed by the invention have the beneficial effects that different preparation processes are adopted for different raw materials to obtain different products, then the different products are primarily fermented and secondarily fermented, and the obtained finished product can cause great reduction of both the disease attack rate and the disease attack index of the aeroponic-cultured lettuces, so that the monetary cost and the labor cost of producers are reduced and the economic benefit is improved.

This invention relates to novel deuterated compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. In particular, this invention relates to novel substituted xanthine derivatives that are deuterated derivatives of a pentoxifylline metabolite. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed deuterated compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial. The compounds of the invention are represented by the following structural formula:wherein the values of R1, R2, R3, R4, R5, Y1 and Y2 are described herein.

The invention belongs to the field of medicine, and particularly relates to a medicinal composition for treating or preventing neuropathic pain. At present, an effective medicament for treating neuropathic pain is unavailable. The invention provides a medicinal composition for treating neuropathic pain. The medicinal composition contains pregabalin and pentoxifylline, and can further contain diclofenac or a pharmaceutical salt thereof. Compared with separate application of pentoxifylline, pregabalin or diclofenac, the medicinal composition which contains pregabalin and pentoxifylline and further contains diclofenac has a synergistic action on the aspect of treatment of neuropathic pain and a particularly better effect on neuropathic pain caused by diabetes mellitus.